BioMarin Reports Third-Quarter Revenue of $1.02 Billion
Revenue rose 32% from $776.1 million a year earlier. Net loss widened to $122.8 million from $30.7 million, and diluted loss per share increased to $0.63 from $0.16.
BioMarin Pharmaceutical reported third-quarter 2026 revenue of $1.02 billion, up 32% from $776.1 million a year earlier, while its net loss widened to $122.8 million from $30.7 million and diluted loss per share increased to $0.63 from $0.16.Financial HighlightsBusiness HighlightsOriginal SEC Filin…